Authors:
PE Hall, R Lewis, N Syed, R Shaffer, J Evanson, S Ellis, M Williams, X Feng, A Johnston, JA Thomson, FP Harris, R Jena, T Matys, S Jefferies, K Smith, B-W Wu, JS Bomalaski, T Crook, K O'Neill, D Paraskevopoulos, RS Khadeir, M Sheaff, S Pacey, PN Plowman, PW Szlosarek
Journal name: 
Clin Cancer Res
Abstract: 
PURPOSE: Patients with recurrent high-grade gliomas (HGGs) are usually managed with alkylating chemotherapy +/- bevacizumab. However, prognosis remains very poor. Pre-clinically, we showed that HGGs are a target for arginine depletion with pegargiminase (ADI-PEG20) due to epimutations of argininosuccinate synthetase (ASS1) and/or argininosuccinate lyase (ASL). Moreover, ADI-PEG20 disrupts pyrimidine pools in ASS1-deficient HGGs, thereby impacting sensitivity to the antifolate, pemetrexed. EXPERIMENTAL DESIGN: We expanded a Phase I trial of ADI-PEG20 with pemetrexed and cisplatin (ADIPEMCIS) to patients with ASS1-deficient recurrent HGGs (NCT02029690). Patients were enrolled (01/16 - 06/17) to receive weekly ADI-PEG20 36 mg/m2 intramuscularly plus pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 intravenously once every three weeks for up to six cycles. Patients with disease control were allowed ADI-PEG20 maintenance. The primary endpoints were safety, tolerability and preliminary estimates of efficacy. RESULTS: Ten ASS1-deficient heavily pre-treated patients were treated with ADIPEMCIS therapy. Treatment was well tolerated with the majority of adverse events being CTCAE v4.03 grade 1-2. The best overall response was stable disease in 8 patients (80%). Plasma arginine was suppressed significantly below baseline with a reciprocal increase in citrulline during the sampling period. The anti-ADI-PEG20 antibody titer rose during the first four weeks of treatment before reaching a plateau. Median progression-free survival (PFS) was 5.2 months (95% CI 2.5-20.8) and overall survival (OS) was 6.3 months (95% CI 1.8-9.7). CONCLUSIONS: In this recurrent HGG study, ADIPEMCIS was well tolerated and compares favorably to historical controls. Additional trials of ADI-PEG20 in HGG are planned.
DOI: 
http://doi.org/10.1158/1078-0432.CCR-18-3729
E-pub date: 
31 Jan 2019
Users with this publication listed: 
Simon Pacey